tilavac volta formulation: each 0.1 ml (dose) contains: streptococcus agalactiae scrotype lb (ti098 strain) ≥ 1.8 x 108 cfu cfu - colony forming unit emulsion for injection (ip)
virbac philippines inc.; distributor: virbac philippines inc. - inactivated streptococcus agalactiae fish vaccine (vet.) - emulsion for injection (ip) - formulation: each 0.1 ml (dose) contains: streptococcus agalactiae scrotype lb (ti098 strain) ≥ 1.8 x 108 cfu cfu - colony forming unit
tilavac s3 each 0.1 ml (dose) contains: streptococcus agalactiae serotype ib (t1098 strain)≥ 1.8 x 108 cfu streptococcus agalactiae serotype ia (ti191 strain)≥ 1.8 x 108 cfu streptococcus agalactiae serotype iii (ti198 strain) ≥ 1.8 x 108 cfu cfu - colony forming unit emulsion for injection (ip)
virbac philippines inc.; distributor: virbac philippines inc. - inactivated streptococcus agalactiae ser. ia, ib, iii fish vaccine (vet.) - emulsion for injection (ip) - each 0.1 ml (dose) contains: streptococcus agalactiae serotype ib (t1098 strain)≥ 1.8 x 108 cfu streptococcus agalactiae serotype ia (ti191 strain)≥ 1.8 x 108 cfu streptococcus agalactiae serotype iii (ti198 strain) ≥ 1.8 x 108 cfu cfu - colony forming unit
prevenar 13 vaccine suspension for injection 0.5ml pre-filled syringes
pfizer ltd - streptococcus pneumoniae capsular polysaccharide protein conjugate - suspension for injection
synflorix vaccine suspension for injection 0.5ml pre-filled syringes
glaxosmithkline uk ltd - streptococcus pneumoniae capsular polysaccharide protein conjugate - suspension for injection
strangvac
intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - immunologicals for equidae - horses - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.
synflorix 4-dose vaccine suspension for injection
glaxosmithkline pharmaceutical sdn. bhd. - streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae; streptococcus pneumoniae -
pneumovax 23- pneumococcal vaccine polyvalent injection, solution
merck sharp & dohme llc - streptococcus pneumoniae type 1 capsular polysaccharide antigen (unii: h9noi61uh1) (streptococcus pneumoniae type 1 capsular polysaccharide antigen - unii:h9noi61uh1), streptococcus pneumoniae type 2 capsular polysaccharide antigen (unii: e11p4f3x4s) (streptococcus pneumoniae type 2 capsular polysaccharide antigen - unii:e11p4f3x4s), streptococcus pneumoniae type 3 capsular polysaccharide antigen (unii: 4fvb62aff1) (streptococcus pneumoniae type 3 capsular polysaccharide antigen - unii:4fvb62aff1), strep - streptococcus pneumoniae type 1 capsular polysaccharide antigen 25 ug in 0.5 ml - pneumovax® 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19f, 19a, 20, 22f, 23f, and 33f). pneumovax 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease. pneumovax 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. do not administer pneumovax 23 to individuals with a history of anaphylactic/anaphylactoid or severe allergic reaction to any component of the vaccine. [see description (11).] risk summary all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. available human data from clinical trials of
biotox bac 2- streptococcus viridans, chlamydia trachomatis, bacillus tetani, meningococcus nosode, phytolacca decandra, strepto
the wellness center for research and education, inc. - streptococcus viridans group (unii: nnv2379hkr) (streptococcus viridans group - unii:nnv2379hkr), chlamydia trachomatis (unii: t6ni39qu44) (chlamydia trachomatis - unii:t6ni39qu44), clostridium tetani (unii: 751e8j54vm) (clostridium tetani - unii:751e8j54vm), neisseria meningitidis (unii: v3tp2md7f3) (neisseria meningitidis - unii:v3tp2md7f3), phytolacca americana root (unii: 11e6vi8veg) (phytolacca americana root - unii:11e6vi8veg), streptococcus agalactiae (unii: 2b3763s671) (streptococcus agalactia - for temporary relief of inflammation, fever, coughing, aching, soreness, limb pain, pale skin, cold hands and feet, rash, sinus and/or throat mucus, glandular swelling, vaginal discharge, vaginal itching, burning when urinating. for tempoary relief of inflammation, fever, coughing, aching, soreness, limb pain, pale skin, cold hands and feet, rash, sinus and/or throat mucus, glandular swelling, vaginal discharge, vaginal itcdhing, burning when urinating.
streptococcinum- streptococcus pyogenes pellet
boiron - streptococcus pyogenes (unii: lj2lp0yl98) (streptococcus pyogenes - unii:lj2lp0yl98) - rx only* stop use and ask a doctor if symptoms persist for more than 3 days or worsen
streptococcinum- streptococcus pyogenes pellet
boiron - streptococcus pyogenes (unii: lj2lp0yl98) (streptococcus pyogenes - unii:lj2lp0yl98) - rx only* stop use and ask a doctor if symptoms persist for more than 3 days or worsen